Pharmacogenetics of tenofovir treatment (Q37618231)

21 August 2017

1 reference

title

Pharmacogenetics of tenofovir treatment (English)

1 reference

21 August 2017

1 reference

3

Vincent Soriano

1 reference

21 August 2017

Sonia Rodriguez-Novoa

series ordinal

1

1 reference

PubMed ID

19842939

21 August 2017

Pablo Labarga

series ordinal

2

1 reference

21 August 2017

1 October 2009

1 reference

21 August 2017

1 reference

21 August 2017

10

1 reference

21 August 2017

10

1 reference

21 August 2017

1675-1685

1 reference

Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study.

21 August 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

The safety of tenofovir disoproxil fumarate for the treatment of HIV infection in adults: the first 4 years.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Rapid communication: acute renal failure associated with tenofovir: evidence of drug-induced nephrotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Antiretroviral therapy with tenofovir is associated with mild renal dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Fanconi syndrome and renal failure induced by tenofovir: a first case report

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Tenofovir exhibits low cytotoxicity in various human cell types: comparison with other nucleoside reverse transcriptase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Rosiglitazone reverses tenofovir-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Down-regulation of Na+ transporters and AQP2 is responsible for acyclovir-induced polyuria and hypophosphatemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Transformation and transport: how does metabolic transformation change the affinity of substrates for the renal contraluminal anion and cation transporters?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Human renal organic anion transporter 1 (hOAT1) and its role in the nephrotoxicity of antiviral nucleotide analogs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Mechanism of active renal tubular efflux of tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Renal transport of adefovir, cidofovir, and tenofovir by SLC22A family members (hOAT1, hOAT3, and hOCT2).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Conjugate export pumps of the multidrug resistance protein (MRP) family: localization, substrate specificity, and MRP2-mediated drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Clinical and genetic determinants of intracellular tenofovir diphosphate concentrations in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Pharmacogenetic characteristics of indinavir, zidovudine, and lamivudine therapy in HIV-infected adults: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Intestinal absorption enhancement of the ester prodrug tenofovir disoproxil fumarate through modulation of the biochemical barrier by defined ester mixtures.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Tenofovir-associated acute and chronic kidney disease: a case of multiple drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Role of purine nucleoside phosphorylase in interactions between 2',3'-dideoxyinosine and allopurinol, ganciclovir, or tenofovir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

96-week comparison of once-daily atazanavir/ritonavir and twice-daily lopinavir/ritonavir in patients with multiple virologic failures

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Tenofovir disoproxil fumarate: clinical pharmacology and pharmacokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Greater tenofovir-associated renal function decline with protease inhibitor-based versus nonnucleoside reverse-transcriptase inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Antiviral drug-induced nephrotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Biological effects of short-term or prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (tenofovir) to newborn and infant rhesus macaques

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Phase i/ii trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in human immunodeficiency virus-infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

The private sector and HIV/AIDS in Africa: taking stock of 6 years of applied research

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

The role of CFTR and SPINK-1 mutations in pancreatic disorders in HIV-positive patients: a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Functional consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5'-untranslated region and exon 28.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Evaluation of hypophosphataemia in tenofovir disoproxil fumarate (TDF)-exposed and TDF-unexposed HIV-infected out-patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

Tenofovir renal safety in HIV-infected patients: Results from the SCOLTA Project

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.09.115

21 January 2018

Identifiers

DOI

10.2217/PGS.09.115

1 reference

21 August 2017

1 reference

PubMed ID

19842939